Multiple Electrolytes pH 5.5 sodium chloride, sodium gluconate, sodium acetate, potassium chloride and magnesium 526 mg/100mL; 502 mg/100mL; 368 mg/100mL; 37 mg/100mL; 30 mg/100mL Injection, Solution — NDC 65219-387-05 (Billing 65219-0387-05)
This is a package of Multiple Electrolytes pH 5.5 sodium chloride, sodium gluconate, sodium acetate, potassium chloride and magnesium 526 mg/100mL; 502 mg/100mL; 368 mg/100mL; 37 mg/100mL; 30 mg/100mL Injection, Solution from Fresenius Kabi USA, LLC, marketed since Jul 2021 and currently FDA-listed. It is the main listing for this product, which comes in 2 package sizes.
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 001460
- GCN: 04370
- GPI-14 (Medi-Span): 79992001502000
- HICL (First Databank): 000629
- AHFS class code: 40:12.00.00
- RxCUI (RxNorm): 801109
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 1, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 1, 2026
RxNorm drug class
This medicine belongs to the Electrolyte solutions class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Oct 1, 2026
Clinical
- The IV versions replace water and electrolytes and help balance acid levels. Normosol-R is also used for fluid loss in surgery, trauma, burns or shock. Physiolyte is different: it...
- The IV products are given by healthcare staff through a vein with sterile equipment. Your team decides the amount and speed based on your age, weight and condition. Normosol-R may...
- You might get irritation, infection or a clot near the IV site, or a fever. Too much fluid can also occur. Tell your nurse about any pain or swelling at the site.
- Tell your care team right away about chest pain, trouble breathing, a racing heartbeat, flushing, confusion, seizures, severe weakness or swelling. These could be allergic reaction...
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 1, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Oct 2, 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 65219-0387-05 You're viewing this Main listing | 20 BAG in 1 CASE / 500 mL in 1 BAG | 2022-10-21 | — | Active |
| 65219-0387-10 65219-387-10 | 10 BAG in 1 CASE / 1000 mL in 1 BAG | 2022-10-21 | — | Active |
Pack size FAQ
What quantity is in this package?
What NDC number is used to bill for this package of Multiple Electrolytes pH 5.5 sodium chloride, sodium gluconate, sodium acetate, potassium chloride and magnesium 526 mg/100mL; 502 mg/100mL; 368 mg/100mL; 37 mg/100mL; 30 mg/100mL Injection, Solution?
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Plasma-Lyte A 526 mg/100mL; 502 mg/100mL; 368 mg/100mL; 37 mg/100mL; 30 mg/100mL 00338-0221-03 | Baxter | 500 ml | — | — | FDA listed | — |
| Plasma-Lyte 148 (pH 7.4) 526 mg/100mL; 502 mg/100mL; 368 mg/100mL; 37 mg/100mL; 30 mg/100mL 00338-9593-10 | Baxter | 1000 ml | — | — | FDA listed | — |
| Multiple Electrolytes pH 5.5 526 mg/100mL; 502 mg/100mL; 368 mg/100mL; 37 mg/100mL; 30 mg/100mLthis 65219-0387-05 | Fresenius | 500 ml | — | — | FDA listed | — |
| Multiple Electrolytes pH 7.4 526 mg/100mL; 502 mg/100mL; 368 mg/100mL; 37 mg/100mL; 30 mg/100mL 65219-0389-05 | Fresenius | 500 ml | — | AP | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA Orange Book · refreshed Sep 3, 2026
- CMS NADAC weekly file
Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
- FDA Orange Book · refreshed Sep 3, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII QTT17582CB
A strong acid used to adjust and maintain the proper pH level in liquid medicines, ensuring stability and preventing breakdown of active ingredients.
1 inactive ingredient listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Oct 1, 2026
- FDA openFDA NDC Directory · synced Oct 1, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS AND USAGE Multiple Electrolytes Injection, Type 1, USP, pH 5.5 is indicated as a source of water and electrolytes or as an alkalinizing agent.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION Important Administration Instructions Multiple Electrolytes Injection, Type 1, USP, pH 5.5 is intended for intravenous administration using sterile equipment. Do not connect flexible plastic containers in series in order to avoid air embolism due to possible residual air contained in the primary container. Set the vent to the closed position on a vented intravenous administration set to prevent air embolism.
Use a dedicated line without any connections to avoid air embolism. Do not pressurize intravenous solutions contained in flexible plastic containers to increase flow rates in order to avoid air embolism due to incomplete evacuation of residual air in the container. Prior to infusion, visually inspect the solution for particulate matter and discoloration.
The solution should be clear and there should be no precipitates. Do not administer unless solution is clear, and container is undamaged. Multiple Electrolytes Injection, Type 1, USP, pH 5.5 is compatible with blood or blood components.
It may be administered prior to or following the infusion of blood through the same administration set (i.e., as a priming solution), added to or infused concurrently with blood components, or used as a diluent in the transfusion of packed erythrocytes. Multiple Electrolytes Injection, Type 1, USP, pH 5.5 and 0.9% Sodium Chloride Injection, USP are equally compatible with blood or blood components. Dosing Information The choice of product, dosage, volume, rate, and duration of administration is dependent upon the age, weight and clinical condition of the patient and concomitant therapy, and administration should be determined by a physician experienced in intravenous fluid therapy.
Introduction of Additives Additives may be incompatible. Evaluate all additions to the plastic container for compatibility and stability of the resulting preparation. Consult with a pharmacist, if available.
If, in the informed judgment of the physician, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. After addition, if there is a discoloration and/or the appearance of precipitates, insoluble complexes or crystals, do not use.
Do not store solutions containing additives. Discard any unused portion.
⛔ Contraindications ▾
CONTRAINDICATIONS Multiple Electrolytes Injection, Type 1, USP, pH 5.5 is contraindicated in patients with a known hypersensitivity to the product. See WARNINGS .
⚠️ Warnings ▾
WARNINGS Hypersensitivity Reactions Hypersensitivity and infusion reactions have been reported with Multiple Electrolytes Injection, Type 1, USP. See ADVERSE REACTIONS . Stop the infusion immediately if signs or symptoms of a hypersensitivity reaction develop, such as tachycardia, chest pain, dyspnea and flushing.
Institute appropriate therapeutic countermeasures as clinically indicated. Electrolyte Imbalances Fluid Overload Depending on the volume and rate of infusion, the intravenous administration of Multiple Electrolytes Injection, Type 1, USP can cause electrolyte disturbances such as overhydration and congested states, including pulmonary congestion and edema. Avoid Multiple Electrolytes Injection, Type 1, USP in patients with or at risk for fluid and/or solute overloading.
If use cannot be avoided, monitor fluid balance, electrolyte concentrations, and acid base balance, as needed and especially during prolonged use. Hyponatremia Multiple Electrolytes Injection, Type 1, USP may cause hyponatremia. Hyponatremia can lead to acute hyponatremic encephalopathy characterized by headache, nausea, seizures, lethargy, and vomiting.
Patients with brain edema are at particular risk of severe, irreversible and life-threatening brain injury. The risk of hospital-acquired hyponatremia is increased in patients with cardiac or pulmonary failure, and in patients with non-osmotic vasopressin release (including SIADH) treated with high volume of hypotonic Multiple Electrolytes Injection, Type 1, USP. Avoid Multiple Electrolytes Injection, Type 1, USP in hypervolemic or overhydrated patients.
If use cannot be avoided, monitor serum sodium concentrations. Hypernatremia Hypernatremia may occur with Multiple Electrolytes Injection, Type 1, USP. Conditions that may increase the risk of hypernatremia, fluid overload and edema (central and peripheral), include patients with: primary hyperaldosteronism; secondary hyperaldosteronism associated with, for example, hypertension, congestive heart failure, liver disease (including cirrhosis), renal disease (including renal artery stenosis, nephrosclerosis); and pre-eclampsia.
Certain medications, such as corticosteroids or corticotropin, may also increase risk of sodium and fluid retention, see PRECAUTIONS . Avoid Multiple Electrolytes Injection, Type 1, USP in patients with, or at risk for, hypernatremia. If use cannot be avoided, monitor serum sodium concentrations.
Hypermagnesemia Avoid solutions containing magnesium, including Multiple Electrolytes Injection, Type 1, USP in patients with or predisposed to hypermagnesemia, including patients with severe renal impairment and those patients receiving magnesium therapy (e.g., treatment of eclampsia and myasthenia gravis). Multiple Electrolytes Injection, Type 1, USP is not indicated for the treatment of hypomagnesemia. Acidosis Multiple Electrolytes Injection, Type 1, USP is not for use for the treatment of lactic acidosis or severe metabolic acidosis in patients with severe liver and/or renal impairment.
Alkalosis Excess administration of Multiple Electrolytes Injection, Type 1, USP can result in metabolic alkalosis. Avoid Multiple Electrolytes Injection, Type 1, USP in patients with alkalosis or at risk for alkalosis. Multiple Electrolytes Injection, Type 1, USP is not indicated for the treatment of hypochloremic hypokalemic alkalosis.
Avoid use in patients with hypochloremic hypokalemic alkalosis. Hypocalcemia Multiple Electrolytes Injection, Type 1, USP contains no calcium, and an increase in plasma pH due to its alkalinizing effect may lower the concentration of ionized (not-protein bound) calcium. Avoid Multiple Electrolytes Injection, Type 1, USP in patients with hypocalcemia.
Hyperkalemia Potassium-containing solutions, including Multiple Electrolytes Injection, Type 1, USP may increase the risk of hyperkalemia. Patient's at increased risk of developing hyperkalemia include those: With conditions predisposing to hyperkalemia and/or associated w… [Excerpted — this section continues on DailyMed.]
🤒 Adverse Reactions ▾
ADVERSE REACTIONS Post-marketing Adverse Reactions The following adverse reactions associated with the use of Multiple Electrolytes Injection, Type 1, USP were identified in clinical trials or postmarketing reports. Because postmarketing reactions were reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency, reliably, or to establish a causal relationship to drug exposure. Hypersensitivity and Infusion Reactions : tachycardia, palpitations, chest pain, chest discomfort, dyspnea, flushing, hyperemia, asthenia, feeling abnormal, piloerection, edema peripheral, pyrexia, hypotension, wheezing, urticaria, cold sweat, chills.
General Disorders and Administration Site Conditions : infusion site pain, burning sensation. Metabolism and nutrition disorders : hyperkalemia, hyponatremia. Nervous System Disorders : hyponatremic encephalopathy.
To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
🔄 Drug Interactions ▾
Drug Interactions Other Products that Affect Fluid and/or Electrolyte Balance Administration of Multiple Electrolytes Injection, Type 1, USP to patients treated concomitantly with drugs associated with sodium and fluid retention may increase the risk of hypernatremia and volume overload. Avoid use of Multiple Electrolytes Injection, Type 1, USP in patients receiving such products, such as corticosteroids or corticotropin. If use cannot be avoided, monitor serum electrolytes, fluid balance and acid-base balance.
Other Drugs that Increase the Risk of Hyponatremia Administration of Multiple Electrolytes Injection, Type 1, USP in patients treated concomitantly with medications associated with hyponatremia may increase the risk of developing hyponatremia. Avoid use of Multiple Electrolytes Injection, Type 1, USP in patients receiving products, such as diuretics, and certain antiepileptic and psychotropic medications. Drugs that increase the vasopressin effect reduce renal electrolyte free water excretion and may also increase the risk of hyponatremia following treatment with intravenous fluids.
If use cannot be avoided, monitor serum sodium concentrations. Lithium Renal clearance of lithium may be increased during administration of Multiple Electrolytes Injection, Type 1, USP. Monitor serum lithium concentrations during concomitant use.
Other Products that Increase the Risk of Hyperkalemia Because of its potassium content, avoid use of Multiple Electrolytes Injection, Type 1, USP in patients receiving products that can cause hyperkalemia or increase the risk of hyperkalemia, such as potassium sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine. If use cannot be avoided, monitor serum potassium concentrations. Drugs with pH Dependent Renal Elimination Due to its alkalinizing effect (formation of bicarbonate), Multiple Electrolytes Injection, Type 1, USP may interfere with the elimination of drugs with pH dependent renal elimination.
Renal clearance of acidic drugs may be increased. Renal clearance of alkaline drugs may be decreased.
🔄 Drug / Laboratory Test Interactions ▾
Drug/Laboratory Test Interactions There have been reports of positive test results using the Bio-Rad Laboratories Platelia Aspergillus EIA test in patients receiving gluconate containing Multiple Electrolytes Injection, Type 1, USP solutions. These patients were subsequently found to be free of Aspergillus infection. Therefore, positive test results for this test in patients receiving gluconate containing Multiple Electrolytes Injection, Type 1, USP solutions should be interpreted cautiously and confirmed by other diagnostic methods.
🤰 Pregnancy ▾
Pregnancy Teratogenic Effects Animal reproduction studies have not been conducted with Multiple Electrolytes Injection, Type 1, USP. It is also not known whether Multiple Electrolytes Injection, Type 1, USP can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Multiple Electrolytes Injection, Type 1, USP should be given to a pregnant woman only if clearly needed.
🧒 Pediatric Use ▾
Pediatric Use The use of Multiple Electrolytes Injection, Type 1, USP in pediatric patients is based on clinical practice.
🧓 Geriatric Use ▾
Geriatric Use Geriatric patients are at increased risk of developing electrolyte imbalances. Multiple Electrolytes Injection, Type 1, USP is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Therefore, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Consider monitoring renal function in elderly patients.
🆘 Overdosage ▾
OVERDOSAGE Excessive administration of Multiple Electrolytes Injection, Type 1, USP, pH 5.5 can cause: fluid overload with a risk of edema (peripheral and/or pulmonary), particularly when renal sodium excretion is impaired. hypernatremia and hyperkalemia, especially in patients with severe renal impairment. hypermagnesemia. See WARNINGS and ADVERSE REACTIONS metabolic alkalosis with or without hypokalemia and decreased ionized serum calcium and magnesium concentrations. When assessing an overdose, any additives in the solution must also be considered.
The effects of an overdose may require immediate medical attention and treatment. Interventions include discontinuation of Multiple Electrolytes Injection, Type 1, USP, pH 5.5, dose reduction, and other measures as indicated for the specific clinical constellation (e.g., monitoring of fluid balance, electrolyte concentrations and acid base balance).
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Multiple Electrolytes Injection, Type 1, USP, pH 5.5 has value as a source of water and electrolytes. It is capable of inducing diuresis depending on the clinical condition of the patient. Multiple Electrolytes Injection, Type 1, USP, pH 5.5 produces a metabolic alkalinizing effect. Acetate and gluconate ions are metabolized ultimately to carbon dioxide and water, which requires the consumption of hydrogen cations.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Multiple Electrolytes Injection, Type 1, USP, pH 5.5 in free flex ® plastic containers is available as shown below: Product Code Unit of Use Unit of Sale 387150 NDC 65219-387-00 One 500 mL free flex ® Bag NDC 65219-387-05 Package of 20 free flex ® Bags 387100 NDC 65219-387-02 One 1000 mL free flex ® Bag NDC 65219-387-10 Package of 10 free flex ® Bags Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Brief exposure up to 40°C does not adversely affect the product.
The container closure is not made with natural rubber latex. Non-PVC, Non-DEHP, Sterile.
📋 Description ▾
DESCRIPTION Multiple Electrolytes Injection, Type 1, USP, pH 5.5 is a sterile, nonpyrogenic isotonic solution in a single dose container for intravenous administration. Each 100 mL contains 526 mg of Sodium Chloride, USP (NaCl); 502 mg of Sodium Gluconate (C 6 H 11 NaO 7 ); 368 mg of Sodium Acetate Trihydrate, USP (C 2 H 3 NaO 2 •3H 2 O); 37 mg of Potassium Chloride, USP (KCl); and 30 mg of Magnesium Chloride, USP (MgCl 2 •6H 2 O). It contains no antimicrobial agents.
The pH is adjusted with hydrochloric acid. The pH is 5.5 (4.0 to 8.0). Multiple Electrolytes Injection, Type 1, USP, pH 5.5 administered intravenously has value as a source of water, electrolytes, and calories.
One liter has an ionic concentration of 140 mEq sodium, 5 mEq potassium, 3 mEq magnesium, 98 mEq chloride, 27 mEq acetate, and 23 mEq gluconate. The osmolarity is 294 mOsmol/L (calc). Normal physiologic osmolarity range is approximately 280 to 310 mOsmol/L.
The caloric content is 21 kcal/L. The flexible plastic container is fabricated from a specially formulated non-plasticized, film containing polypropylene and thermoplastic elastomers ( free flex ® bag). The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly.
Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period. However, the safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by tissue culture toxicity studies.
⚠️ Precautions ▾
PRECAUTIONS Patients with Renal Impairment In patients with renal impairment, administration of Multiple Electrolytes Injection, Type 1, USP may result in sodium and/or potassium or magnesium retention (see WARNINGS ). Avoid Multiple Electrolytes Injection, Type 1, USP in patients with severe renal impairment or conditions that may cause sodium and/or potassium retention or magnesium retention, fluid overload, or edema. If use cannot be avoided, monitor patients with severe renal impairment for development of these adverse reactions.
Drug Interactions Other Products that Affect Fluid and/or Electrolyte Balance Administration of Multiple Electrolytes Injection, Type 1, USP to patients treated concomitantly with drugs associated with sodium and fluid retention may increase the risk of hypernatremia and volume overload. Avoid use of Multiple Electrolytes Injection, Type 1, USP in patients receiving such products, such as corticosteroids or corticotropin. If use cannot be avoided, monitor serum electrolytes, fluid balance and acid-base balance.
Other Drugs that Increase the Risk of Hyponatremia Administration of Multiple Electrolytes Injection, Type 1, USP in patients treated concomitantly with medications associated with hyponatremia may increase the risk of developing hyponatremia. Avoid use of Multiple Electrolytes Injection, Type 1, USP in patients receiving products, such as diuretics, and certain antiepileptic and psychotropic medications. Drugs that increase the vasopressin effect reduce renal electrolyte free water excretion and may also increase the risk of hyponatremia following treatment with intravenous fluids.
If use cannot be avoided, monitor serum sodium concentrations. Lithium Renal clearance of lithium may be increased during administration of Multiple Electrolytes Injection, Type 1, USP. Monitor serum lithium concentrations during concomitant use.
Other Products that Increase the Risk of Hyperkalemia Because of its potassium content, avoid use of Multiple Electrolytes Injection, Type 1, USP in patients receiving products that can cause hyperkalemia or increase the risk of hyperkalemia, such as potassium sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine. If use cannot be avoided, monitor serum potassium concentrations. Drugs with pH Dependent Renal Elimination Due to its alkalinizing effect (formation of bicarbonate), Multiple Electrolytes Injection, Type 1, USP may interfere with the elimination of drugs with pH dependent renal elimination.
Renal clearance of acidic drugs may be increased. Renal clearance of alkaline drugs may be decreased. Drug/Laboratory Test Interactions There have been reports of positive test results using the Bio-Rad Laboratories Platelia Aspergillus EIA test in patients receiving gluconate containing Multiple Electrolytes Injection, Type 1, USP solutions.
These patients were subsequently found to be free of Aspergillus infection. Therefore, positive test results for this test in patients receiving gluconate containing Multiple Electrolytes Injection, Type 1, USP solutions should be interpreted cautiously and confirmed by other diagnostic methods. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies with Multiple Electrolytes Injection, Type 1, USP have not been performed to evaluate carcinogenic potential, mutagenic potential, or effects on fertility.
Pregnancy Teratogenic Effects Animal reproduction studies have not been conducted with Multiple Electrolytes Injection, Type 1, USP. It is also not known whether Multiple Electrolytes Injection, Type 1, USP can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Multiple Electrolytes Injection, Type 1, USP should be given to a pregnant woman only if clearly needed.
Nursing Mothers It is not known where this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Mul… [Excerpted — this section continues on DailyMed.]
🍼 Nursing Mothers ▾
Nursing Mothers It is not known where this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Multiple Electrolytes Injection, Type 1, USP is administered to a nursing mother.
📄 Carcinogenesis, Mutagenesis, Impairment of Fertility ▾
Carcinogenesis, Mutagenesis, Impairment of Fertility Studies with Multiple Electrolytes Injection, Type 1, USP have not been performed to evaluate carcinogenic potential, mutagenic potential, or effects on fertility.
📖 Instructions for Use ▾
INSTRUCTIONS FOR USE For Information on Risk of Air Embolism – see DOSAGE AND ADMINISTRATION . Check solution container composition, lot number, and expiry date. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Do not use solution containers in series connections. Do not remove solution container from its overwrap until immediately before use. The intact port caps provide visual tamper evidence.
Do not use if a port cap is prematurely removed. Maintain strict aseptic technique during handling. TO OPEN Always inspect the solution container before and after removal from the overwrap.
Place the solution container on a clean, flat surface. Using the pre-cut corner tabs, peel open the overwrap and remove the solution container from the overwrap. Check the solution container for leaks by squeezing firmly.
If leaks are found, discard as sterility may be impaired. Do not use if the solution is cloudy or a precipitate is present. TO PREPARE FOR ADMINISTRATION Immediately before inserting the infusion set, break off BLUE Infusion Port Cap with the arrow pointing away from the solution container.
Use a non-vented infusion set or close the air-inlet on a vented set. Close the roller clamp of the infusion set. Hold the base of BLUE Infusion Port, twist and push the spike until the spike is fully inserted.
Refer to complete directions accompanying set. The BLUE infusion port contains a self‐sealing septum that helps prevent leakage after removing the spike. The infusion port is not intended to be spiked more than once.
Suspend solution container from hanger hole. If supplemental medication is desired, follow directions below. TO ADD MEDICATION BEFORE SOLUTION ADMINISTRATION Identify WHITE Injection Port with arrow pointing toward solution container.
Immediately before injecting additives, break off WHITE Injection Port Cap with the arrow pointing toward solution container. Hold base of WHITE Injection Port. Insert needle (18 to 23 gauge) through the center of WHITE Injection Port's septum and inject additives.
Mix solution container contents thoroughly. For high density medication such as potassium chloride, squeeze ports while ports are upright and mix thoroughly. TO ADD MEDICATION DURING SOLUTION ADMINISTRATION Close the clamp on the set.
Identify WHITE Injection Port with arrow pointing toward solution container. Immediately before injecting additives, break off WHITE Injection Port cap with the arrow pointing toward solution container. Hold base of WHITE Injection Port.
Insert needle (18 to 23 gauge) through the center of WHITE Injection Port's septum and inject additives. Remove container from IV pole and/or turn to an upright position. Evacuate both ports by squeezing them while container is in the upright position.
Mix solution container contents thoroughly. Return container to in use position and continue administration. For Single Use Only.
Discard unused portion. Manufactured for: Lake Zurich, IL 60047 Made in Germany 451766 www.fresenius-kabi.com/us Issued: September 2022 Fresenius Kabi Logo
📄 Package Label / Principal Display Panel ▾
PACKAGE LABEL - PRINCIPAL DISPLAY – Multiple Electrolytes Injection, Type 1, USP pH 5.5 500 mL Bag Label 500 mL NDC 65219-387-00 Multiple Electrolytes Injection, Type 1, USP pH
5.5Rx only Each 100 mL contains : 526 mg Sodium Chloride, USP; 502 mg Sodium Gluconate, USP; 368 mg Sodium Acetate Trihydrate, USP; 37 mg Potassium Chloride, USP; 30 mg Magnesium Chloride, USP pH adjusted with Hydrochloric acid. Electrolytes per 1,000 mL: Sodium 140 mEq; Potassium 5 mEq; Magnesium 3 mEq; Chloride 98 mEq; Acetate 27 mEq; Gluconate 23 mEq 294 mOsmol/Liter (Calc.) pH 5.5 (4.0 to 8.0) PACKAGE LABEL - PRINCIPAL DISPLAY – Multiple Electrolytes Injection, Type 1, USP pH 5.5 500 mL Bag Label
PACKAGE LABEL – PRINCIPAL DISPLAY – Multiple Electrolytes Injection, Type 1, USP pH 5.5 500 mL Shipper Label NDC 65219-387-05 387150 Multiple Electrolytes Injection, Type 1, USP pH 5.5 500 mL x 20 STORE AT: 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature] until ready to use. Avoid excessive heat. PACKAGE LABEL – PRINCIPAL DISPLAY – Multiple Electrolytes Injection, Type 1, USP pH 5.5 500 mL Shipper Label
PACKAGE LABEL - PRINCIPAL DISPLAY – Multiple Electrolytes Injection, Type 1, USP pH 5.5 1000 mL Bag Label 1000 mL NDC 65219-387-02 Multiple Electrolytes Injection, Type 1, USP pH
5.5Rx only Each 100 mL contains : 526 mg Sodium Chloride, USP; 502 mg Sodium Gluconate, USP; 368 mg Sodium Acetate Trihydrate, USP; 37 mg Potassium Chloride, USP; 30 mg Magnesium Chloride, USP pH adjusted with Hydrochloric acid. Electrolytes per 1,000 mL: Sodium 140 mEq; Potassium 5 mEq; Magnesium 3 mEq; Chloride 98 mEq; Acetate 27 mEq; Gluconate 23 mEq 294 mOsmol/Liter (Calc.) pH 5.5 (4.0 to 8.0) PACKAGE LABEL - PRINCIPAL DISPLAY – Multiple Electrolytes Injection, Type 1, USP pH 5.5 1000 mL Bag Label
PACKAGE LABEL – PRINCIPAL DISPLAY – Multiple Electrolytes Injection, Type 1, USP pH 5.5 1000 mL Shipper Label NDC 65219-387-10 387100 Multiple Electrolytes Injection, Type 1, USP pH 5.5 1000 mL x 10 STORE AT: 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature] until ready to use. Avoid excessive heat. PACKAGE LABEL – PRINCIPAL DISPLAY – Multiple Electrolytes Injection, Type 1, USP pH 5.5 1000 mL Shipper Label
About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |